Skip to main content
OpenTrials

Clinical trial condition

Nevi and Melanomas

Explore clinical trials studying Nevi and Melanomas. Study availability and eligibility vary by location and protocol.

2,361 public trials 406 recruiting studies
Refine in advanced search Browse all conditions

Nevi and Melanomas trial results

Active, Not Recruiting

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

NCT02817633

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +26 more
Locations
  • GSK Investigational Site Goodyear, Arizona, United States
  • GSK Investigational Site Scottsdale, Arizona, United States
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Tucson, Arizona, United States
View all 89 locations
View Trial Details
Active, Not Recruiting

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

NCT04056247

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +23 more
Locations
  • Birmingham VAHCS Birmingham, Alabama, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • University of Miami Miami, Florida, United States
  • Florida Cancer Specialist and Research Institute Orlando, Florida, United States
View all 41 locations
View Trial Details
Active, Not Recruiting

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

NCT04139902

Conditions
Melanoma, Melanoma Stage III, Melanoma Stage IV, +11 more
Locations
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Intrathecal Double Checkpoint Inhibition

NCT05598853

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +25 more
Locations
  • University Hospital Zurich Zurich, Canton of Zurich, Switzerland
  • University Hospital Basel Basel, Switzerland
  • University Hospital Geneva Geneva, Switzerland
View Trial Details
Active, Not Recruiting

A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

NCT06540391

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
Locations
  • Centre Georges Francois Leclerc Dijon, France
  • CHU de Lille - Hopital Claude Huriez Lille, France
  • Centre Leon Berard Lyon, France
  • AP-HM - Hopital de la Timone Marseille, France
View all 19 locations
View Trial Details
Active, Not Recruiting

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

NCT04606472

Conditions
Adenocarcinoma, Breast Diseases, Breast Neoplasms, +43 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Chongqing University Cancer Hospital Chongqing, Chongqing Municipality, China
  • The First Affiliated Hospital of Xiamen University Xiamen, Fujian, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
View Trial Details
Active, Not Recruiting

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

NCT04674683

Conditions
Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, +17 more
Locations
  • Comprehensive Blood and Cancer Center Bakersfield, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Innovative Clinical Research Institute (ICRI) Pasadena, California, United States
  • Emad Ibrahim, MD, INC Redlands, California, United States
View all 139 locations
View Trial Details
Active, Not Recruiting

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
Locations
  • Highlands Oncology Group ( Site 1943) Springdale, Arkansas, United States
  • UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1918) Los Angeles, California, United States
  • UCSF Medical Center at Mission Bay ( Site 1929) San Francisco, California, United States
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 1933) New Haven, Connecticut, United States
View all 165 locations
View Trial Details

Related conditions